NTLA: Pendapatan dodolan perusahaan Intellia Therapeutics Inc

Lambang korporat lan logo Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics (NTLA) leads the genome editing rights sector while avoiding price wars. The company's sold products demonstrate the dynamics of the business's fundamental share, where the 0.05 mark reflects the latest data. Revenues are based on future sales of CRISPR drugs for ATTR and edema. However, mutation risks and regulatory complexities create financial uncertainty for investors.

NTLA: Pendapatan lan volume dodolan Intellia Corp 04.07.2022 - 17.11.2026

Rincian analitis perusahaan Intellia Therapeutics

Ringkesan analisis perusahaan:NTLA, intelliatx.com
Produk asli Intellia Therapeutics Inc

Intellia Therapeutics sales reflect daily cash inflows from product realization, allowing for the identification of hidden business degradation during periods of low market valuation. Growth in this metric confirms an expansion of operational scale, while a decline signals risks to margin positions. By analyzing the sales trajectory of Intellia Therapeutics, an investor assesses the effectiveness of technology commercialization. For Intellia Therapeutics (NTLA), this indicator characterizes the monetization of its developments. Outsourcing production and trials allows the company to focus on DNA innovations.

Analisis perusahaan pesaing

Tempus AI, Inc. (TEM) - Pendapatan reged perusahaan|Dodolan perusahaan QGEN (Qiagen NV)|Pendapatan lan volume dodolan Ionis Pharmaceuticals, Inc. (IONS)|Pendapatan lan volume dodolan RGEN (Repligen Inc.)|Avidity Corp (RNA) - Total pendapatan perusahaan|CRSP - Pendapatan perusahaan|Pendapatan reged perusahaan genedx.com WGS|Ultragenyx Pharmaceutical (RARE) - Pendapatan perusahaan|Total pendapatan perusahaan Beam Therapeutics Corp (BEAM)|SRPT (Sarepta Therapeutics) - Pendapatan lan volume dodolan|Total pendapatan perusahaan Twist Bioscience Corp TWST|Pendapatan lan volume dodolan TXG|Pendapatan lan volume dodolan Stoke Therapeutics, Inc. (STOK)|Pendapatan perusahaan BioLife BLFS|WVE - Dodolan perusahaan|Maze Therapeutics Corp - Pendapatan lan volume dodolan|Sionna Pharma - Total dodolan perusahaan|Prime Medicine (PRME) - Pendapatan perusahaan|tayshagtx.com (TSHA) - Pendapatan lan volume dodolan|Pendapatan perusahaan uniQure Corp|MGTX: Pendapatan dodolan perusahaan|Pendapatan lan volume dodolan RGNX|Pendapatan reged perusahaan Solid Corp|Pendapatan lan volume dodolan OCGN (ocugen.com)|PACB (Pacific Biosciences) - Pendapatan tahunan perusahaan|Benitec Biopharma Inc - Pendapatan lan volume dodolan|Pendapatan reged perusahaan Design Therapeutics, Inc. DSGN|Rocket Corp (RCKT) - Pendapatan perusahaan|4D Molecular Therapeutics (FDMT) - Pendapatan lan volume dodolan|LXEO (Lexeo Therapeutics, Inc.) - Pendapatan lan volume dodolan|Total pendapatan perusahaan korrobio.com KRRO|Dodolan perusahaan EDIT (Editas Medicine, Inc.)|Silence Therapeutics plc - Volume dodolan perusahaan|Pendapatan perusahaan ProQR Therapeutics N.V. PRQR|Pendapatan reged perusahaan Codexis, Inc. (CDXS)|SGMO - Pendapatan perusahaan|nautilus.bio - Total dodolan perusahaan|Metagenomi, Inc (MGX) - Pendapatan perusahaan|Volume dodolan perusahaan DTIL|Pendapatan perusahaan Generation Bio|Pendapatan lan volume dodolan Boundless Bio Inc|Pendapatan perusahaan Exicure Corp (XCUR)|Pendapatan reged perusahaan Imunon|Pendapatan lan volume dodolan PHIO (phiopharma.com)|Total volume dodolan perusahaan mustangbio.com|RNAZ - Pendapatan perusahaan|Total pendapatan perusahaan Bionano Genomics|APDN: Pendapatan lan volume dodolan|Volume dodolan perusahaan BLUE|Dodolan perusahaan IPA|OMGA: Pendapatan dodolan perusahaan|Pendapatan lan volume dodolan OMIC|Pendapatan reged perusahaan Regulus Therapeutics|Pendapatan perusahaan Syros SYRS|Pendapatan dodolan perusahaan TBIO|TCON: Dodolan perusahaan|Unity Biotechnology, Inc. (UBX) - Dodolan perusahaan